SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Cooperatieve Gilde Healthcare IV U.A. (Last) (First) (Middle) NEWTONLAAN 91 3584 BP (Street) UTRECHT P7 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Inari Medical, Inc. [ NARI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/12/2021
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2021		S		47,935	D	$115.15(1)	5,893,744	I	See footnote(2)
Common Stock	03/12/2021		S		113,990	D	$115.84(3)	5,779,754	I	See footnote(2)
Common Stock	03/12/2021		S		32,926	D	$116.92(4)	5,746,828	I	See footnote(2)
Common Stock	03/12/2021		S		18,700	D	$117.86(5)	5,728,128	I	See footnote(2)
Common Stock	03/12/2021		S		24,689	D	$119.01(6)	5,703,439	I	See footnote(2)
Common Stock	03/12/2021		S		11,760	D	$119.81(7)	5,691,679	I	See footnote(2)
Common Stock	03/15/2021		S		4,707	D	$113.21(8)	5,686,972	I	See footnote(2)
Common Stock	03/15/2021		S		89,169	D	$114.22(9)	5,597,803	I	See footnote(2)
Common Stock	03/15/2021		S		49,316	D	$115.15(10)	5,548,487	I	See footnote(2)
Common Stock	03/15/2021		S		33,799	D	$116.17(11)	5,514,688	I	See footnote(2)
Common Stock	03/15/2021		S		20,663	D	$116.96(12)	5,494,025	I	See footnote(2)
Common Stock	03/15/2021		S		2,346	D	$117.98(13)	5,491,679	I	See footnote(2)
Common Stock	03/15/2021		S		1,000,000	D	$111.5	4,491,679	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person* Cooperatieve Gilde Healthcare IV U.A. (Last) (First) (Middle) NEWTONLAAN 91 3584 BP (Street) UTRECHT P7 (City) (State) (Zip)

1. Name and Address of Reporting Person* Gilde Healthcare IV Management B.V. (Last) (First) (Middle) NEWTONLAAN 91 3584 BP (Street) UTRECHT P7 (City) (State) (Zip)

1. Name and Address of Reporting Person* Gilde Healthcare Holding B.V. (Last) (First) (Middle) NEWTONLAAN 91 3584 BP (Street) UTRECHT P7 (City) (State) (Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $114.45 to $115.44, inclusive. The Reporting Persons undertake to provide to Inari Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

2. All securities reported are held of record by Cooperatieve Gilde Healthcare IV U.A. ("Gilde"). Gilde is managed by Gilde Healthcare IV Management B.V. ("Management"). Management is owned by Gilde Healthcare Holding B.V. ("Holding"). Each of Management and Holding may be deemed to have voting, investment and dispositive power with respect to the securities held by Gilde. Each of Management and Holding disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities, except to the extent of their respective pecuniary interests therein.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $115.45 to $116.44, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $116.45 to $117.445, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $117.45 to $118.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $118.47 to $119.42, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $119.575 to $120.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $112.655 to $113.63, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $113.67 to $114.665, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $114.6775 to $115.66, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $115.67 to $116.66, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $116.67 to $117.61, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $117.71 to $118.31, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	Cooperatieve Gilde Healthcare IV U.A., By: /s/ Marc Perret, Name: Marc Perret, Title: Managing Director	03/16/2021
	Gilde Healthcare IV Management B.V., By: /s/ Marc Perret, Name: Marc Perret, Title: Managing Director	03/16/2021
	Gilde Healthcare Holding B.V., By: /s/ Marc Perret, Name: Marc Perret, Title: Managing Director	03/16/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.